Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
80.00
-3.72 (-4.44%)
Sep 29, 2026, 4:00 PM EDT - Market closed

Monopar Therapeutics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Monopar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $127.62. The average 1-year stock price forecast is 59.53% higher than the current stock price, while the lowest is $100 (+25.00%) and the highest is $145 (+81.25%).

Price Target: $127.62 (+59.53%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$100$127.62$130$145
Change+25.00%+59.53%+62.50%+81.25%

Analyst Ratings

The average analyst rating for Monopar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Jul '26Aug '26Sep '26
Strong Buy1099988
Buy444444
Hold000011
Sell000000
Strong Sell000000
Total141313131313

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Piper Sandler
Piper Sandler
Buy
Maintains
$101 → $123
BuyMaintains$101 → $123+53.75%Sep 28, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$125
BuyMaintains$125+56.25%Sep 22, 2026
Barclays
Barclays
Buy
Maintains
$128 → $145
BuyMaintains$128 → $145+81.25%Sep 11, 2026
Morgan Stanley
Morgan Stanley
Buy
Reiterates
$115 → $130
BuyReiterates$115 → $130+62.50%Aug 17, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Downgrades
$109 → $119
HoldDowngrades$109 → $119+48.75%Aug 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
28.26M
EPS This Year
-3.04
from -1.85
EPS Next Year
-1.92
from -3.04
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
------
Operating Income
-9.13M-10.54M-8.83M-16.16M-16.70M-27.29M
Net Income
-9.10M-10.52M-8.40M-15.59M-13.72M-21.46M
EPS
-----1.85-3.04
Free Cash Flow
-----12.20M-25.09M
No. Analysts
-----10
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-1.88
Avg-3.04
Low-5.25

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-